CIPROFLOXACIN PHARMACOKINETICS IN PATIENTS WITH CYSTIC-FIBROSIS

被引：36

作者：

BENDER, SW

DALHOFF, A

SHAH, PM

STREHL, R

POSSELT, HG

机构：

[1] BAYER AG,PHARMA RES CTR,D-5600 WUPPERTAL,FED REP GER

[2] ZENTRUM INNEREN MED,D-6000 FRANKFURT 70,FED REP GER

来源：

关键词：

D O I：

10.1007/BF01644804

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：17 / 21

页数：5

共 48 条

[1] DIFFERENCE IN RENAL HANDLING OF CEFSULODIN BETWEEN PATIENTS WITH CYSTIC-FIBROSIS AND NORMAL SUBJECTS
ARVIDSSON, A
ALVAN, G
STRANDVIK, B
[J]. ACTA PAEDIATRICA SCANDINAVICA, 1983, 72 (02): : 293 - 294
[2] INVITRO ACTIVITY OF CIPROFLOXACIN, NORFLOXACIN AND NALIDIXIC-ACID
BAUERNFEIND, A
PETERMULLER, C
[J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1983, 2 (02) : 111 - 115
[3] BENDER SW, 1984, 9TH P INT CYST FIBR
[4] BENDER SW, 1985, 14TH INT C CHEM KYOT
[5] BERGAN T, 1979, ARZNEIMITTEL-FORSCH, V29-2, P1955
[6] BERGAN T, 1986, ANTIMICROB AGENTS CH
[7] BERGOGNEBEREZIN E, 1985, 14TH INT C CHEM KYOT
[8] BLUMER JL, 1985, 14 INT C CHEM KYOT
[9] CIPROFLOXACIN DISTRIBUTION IN PROSTATIC TISSUE AND FLUID FOLLOWING ORAL-ADMINISTRATION
BOEREMA, JBJ
DALHOFF, A
DEBRUYNE, FMY
[J]. CHEMOTHERAPY, 1985, 31 (01) : 13 - 18
[10] BOEREMA JBJ, 1984, LANCET, V2, P695